Dual-Action IgY and Cerium Oxide Nanofibrous Dressings Accelerate Scarless Healing in Infected Wound Models
Posted inDermatology Infectious Diseases news

Dual-Action IgY and Cerium Oxide Nanofibrous Dressings Accelerate Scarless Healing in Infected Wound Models

Researchers have developed a novel P/G@IYCe dressing combining yolk immunoglobulins and cerium oxide nanoparticles. This synergy effectively neutralizes bacterial pathogens and reactive oxygen species, facilitating rapid, high-quality skin regeneration and significantly reducing scar formation in infected full-thickness wound models.
Preexisting Antiviral Immunity and Allogeneic T-Cell Transfer: Redefining the Therapeutic Landscape of Progressive Multifocal Leukoencephalopathy
Posted inInfectious Diseases Neurology news

Preexisting Antiviral Immunity and Allogeneic T-Cell Transfer: Redefining the Therapeutic Landscape of Progressive Multifocal Leukoencephalopathy

Recent studies highlight the critical role of virus-specific T-cells in treating progressive multifocal leukoencephalopathy. Pre-existing T-cells predict superior responses to checkpoint inhibitors, while allogeneic T-cell transfer offers a promising rescue therapy for patients with profound immunodeficiency, significantly reducing viral loads and improving clinical outcomes.
High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status
Posted inDiabetes & Endocrinology Infectious Diseases news Public Health

High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status

A secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines significantly reduce cardiorespiratory and influenza-related hospitalizations in adults aged 65 and older, with consistent benefits observed in patients with diabetes, particularly those with a disease duration exceeding five years.
Delpazolid Emerges as a Safer Oxazolidinone Alternative for Tuberculosis: Results from the PanACEA-DECODE-01 Trial
Posted inInfectious Diseases news Respiratory

Delpazolid Emerges as a Safer Oxazolidinone Alternative for Tuberculosis: Results from the PanACEA-DECODE-01 Trial

The Phase 2b PanACEA-DECODE-01 trial identifies delpazolid 1200 mg once daily as an effective and safer oxazolidinone alternative to linezolid, demonstrating a 38% faster mycobacterial load decline when added to a bedaquiline, delamanid, and moxifloxacin backbone for pulmonary tuberculosis treatment.
Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial
Posted inInfectious Diseases news Respiratory

Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial

The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression typical of linezolid, offering a promising alternative for drug-resistant TB therapy.